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Abstract
Background: Polymorphisms in genes encoding adiponectin (ADIPOQ) and interleukin-6 (IL6) have been associated
with adiposity and obese-related phenotypes. This study investigated the relationship of ADIPOQ and IL6 gene
polymorphisms with pro-inflammatory and cardiometabolic markers in obese patients.
Methods: Anthropometric and body composition parameters were measured in 249 Brazilian subjects (30 to 68 yr).
Metabolic and inflammatory markers and adipokines were analyzed in blood samples. ADIPOQ rs2241766 (45 T > G)
and IL6 rs1800795 (−174G > C) polymorphisms were analyzed by real-time PCR and PCR-RFLP, respectively.
Results: Type 2 diabetes, hypertension, dyslipidemia and increased values of waist circumference, body fat, leptin,
fibrinogen, IL-1β, hsCRP and TNFα were related to obesity (p < 0.05). Multiple linear regression analysis showed a
positive correlation between BMI and waist circumference, body fat, leptin, fibrinogen, PAI-1, IL-1β, hsCRP and TNFα
values (p < 0.001) but not with adiponectin. Obese group had altered metabolic status, resistance to leptin and
insulin, and atherogenic and pro-inflammatory profiles. ADIPOQ and IL6 variants were not directely related to
obesity, leptin resistance or alterations in cardiometabolic markers. Individuals carrying ADIPOQ 45G allele (TG + GG
genotype) had higher IL-6, IL-1β and TNFα levels than TT genotype carriers (p < 0.05). IL6 -174GG genotype was
associated with increased IL-1β levels (p = 0.033).
Conclusion: Obesity is associated with leptin resistance, cardiometabolic alterations and a pro-inflammatory status.
Our results are suggestive that ADIPOQ and IL6 polymorphisms contribute to cardiometabolic risk in obese individuals.
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Background
Obesity is a multifactorial clinical condition caused by
excessive adiposity that is a major contributor to the glo-
bal epidemic of type 2 diabetes (T2DM), fatty liver dis-
ease and cardiovascular disease (CVD) [1,2].
Adipose tissue is a key endocrine organ, which produces
several bioactive molecules (adipokines), such as leptin,
resistin and adiponectin, with pro- or anti-inflammatory
activities [3]. Adipokines are involved in the regulation of
appetite and satiety, energy expenditure, endothelial func-
tion, hemostasis, blood pressure, adipogenesis and fat
distribution, and insulin secretion and sensitivity [4].
Therefore, expansion of adipose tissue changes the secre-
tion of adipokines towards a pro-inflammatory, diabeto-
genic and atherogenic pattern [3-5].
Adiponectin is an adipokine that is involved in the
sensitivity to insulin. Adiponectinemia is markedly de-
creased in individuals with visceral obesity and states of
insulin resistance, such as nonalchoolic fatty liver dis-
ease, atherosclerosis, and T2DM [6]. Therefore, adipo-
nectin has been considered as a biomarker for insulin
resistance, T2DM, metabolic syndrome and cardiovascu-
lar disease.
Adipose tissue also secretes several inflammatory mol-
ecules, including interleukin-6 (IL-6) that has both local
and systemic effects. It has been suggested that IL-6
* Correspondence: rosariohirata@usp.br
1School of Pharmaceutical Sciences, University Sao Paulo, Av. Prof. Lineu
Prestes, 580, 05508-900, Sao Paulo, SP, Brazil
Full list of author information is available at the end of the article
METABOLIC SYNDROME
DIABETOLOGY & 
© 2015 Oliveira et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
de Oliveira et al. Diabetology & Metabolic Syndrome  (2015) 7:34 
DOI 10.1186/s13098-015-0027-2
plays a role in the induction of the inflammatory process
linked to obesity [7].
Common single nucleotide polymorphisms (SNPs) in
adiponectin (ADIPOQ) and IL-6 (IL6) genes have been
shown to be related to obesity and adiposity-related
phenotypes.
The ADIPOQ rs2241766 (45 T >G) and rs1501299
(276G >T, c.214 + 62G >T) SNPs have been associated
with variability in plasma adiponectin levels [8,9]. Moreover,
these variants have been also related to increased body
weight, adiposity, metabolic alterations, insulin resistance,
and risk for T2DM and coronary artery disease (CAD), in
studies from different ethnic populations [10-15].
A common SNP located in the promoter region of IL6,
known as -174G > C (rs1800795, c.-237C > G) variant
was associated with increased risk for overwheight and
obesity-related metabolic disorders, especially insulin re-
sistance in various group populations [16-19]. This IL6
variant was suggested to play a role in the regulation of
body mass through their influence on metabolism and
energetic homeostasis [20].
We have investigated the relationship between ADI-
POQ 45 T > G and IL6 -174G > C variants and obesity
and metabolic markers in a sample of our population.
Subjects and methods
Study subjects
Two-hundred-forty-nine individuals, aged 30 to 68 yr,
were randomly selected at the University Hospital of
University of Sao Paulo, Sao Paulo, Brazil. They were in-
formed about the study protocol and those who agreed
to participate as volunteers have signed the informed
consent. The study protocol was approved by the Ethics
Committees of the School of Pharmaceutical Sciences
and University Hospital of the University of Sao Paulo
(Sao Paulo, Brazil).
Individuals with thyroid, adrenal or gonad dysfunction
or other type of secondary obesity, as well as liver, kid-
ney or gastrointestinal disease, and pregnant women or
under treatment of oral contraceptives were not in-
cluded in the study.
All participants answered a questionnaire to collect
personal information during an interview. Each individ-
ual declared his ethnic group and provide information
about medication use, physical activity, alcohol con-
sumption and cigarette smoking.
Anthropometric measurements, such as body mass
index (BMI), waist circumference, waist-to-hip ratio
(WHR) were taken from each participant. Individuals
were grouped as normoweight (BMI ≤ 24.9 kg/m2), over-
weight (BMI 25.0-29.9 kg/m2) and obese (BMI ≥30 kg/m2).
Body fat and basal metabolic rate (BMR) were measured
using a 310E impedanciometer (RJL Systems, Inc, USA).
Systolic/diastolic blood pressure was measured in su-
pine position after resting for 30 min by a trained phys-
ician using a mercury column sphygmomanometer.
Subjects with systolic/diastolic blood pressure over to
140/90 mmHg or were under anti-hypertensive therapy
were considered hypertensive.
Participants with fasting glycemia over 125 mg/dL
(American Diabetes Association), or taking a glucose-
lowering drug were classified as type 2 diabetics. Current
tobacco smoking was considered as a daily intake of one
or more cigarette. Alcohol consumption was considered
an intake of any dose of beer, wine and/or distilled
spirits according to World Health Organization recom-
mendation. Physical exercise practice was considered the
practice of sports, for example walking, running or
swimming, for at least 2 h per week.
Laboratory tests
Blood samples were drawn for genomic DNA extraction
and measurements of metabolic and inflammatory
markers after fasting for 12 h. Serum glucose, total chol-
esterol, triglycerides and high density lipoprotein (HDL)
cholesterol were measured by enzyme-colorimetric
methods and apolipoprotein (apo) AI and B were deter-
mined by immunoturbidimetry (Siemens Healthcare
Diagnosis Inc., Tarrytown, NY, USA). Values of very-low
(VLDL) and low density lipoprotein (LDL) cholesterol
were calculated.
Fibrinogen was determined using the Fibre Kit-Test
Diagnostica Stago Inc (Bayer/STACompact-Stago, Germany).
High sensitive C reactive protein (hsCRP) and insulin were
determined by immunonephelometry and chemilumines-
cence, respectively (Siemens Healthcare Diagnosis Inc.,
Tarrytown, NY, USA). HbA1c was measured in EDTA-
anticoagulated blood by affinity chromatography (HPLC)
using the D10 Hemoglobin Testing System (Biorad ®, San
Francisco, USA). The homeostasis model assessment
(HOMA) was used for evaluation of the beta-cell secretory
function (HOMA-β) and insulin resistance (HOMA-IR).
Leptin, adiponectin, tumor necrosis factor alpha
(TNFα), IL-6, interleukin 1beta (IL-1β), and plasmino-
gen activator inhibitor 1 (PAI-1) in serum were mea-
sured by Milliplex technology Luminex Map ® 100/200
(Gen-Probe, Austin, TX, USA). Soluble leptin receptor
(sLEPR) was measured by ELISA using kit from ALEXIS
Biochemicals Axxora, LLC (San Diego, CA, USA).
Genetic analysis
Genomic DNA was extracted from peripheral blood leu-
kocytes using the method of affinity chromatography
system using QIAGEN spin-column kits and robotic
workstation to purify DNA QIAcube (Qiagen Biotech-
nology Brasil Ltda, Sao Paulo, Brazil).
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The ADIPOQ 45 T > G (rs2241766) SNP was geno-
typed by TaqMan real time PCR using the pre-designed
assay ID c__26426077_10 for allelic discrimination, con-
taining specif probes for each allele marked with VIC
and FAM fluorescent dyes (Applied Biosystems, Foster
City, USA). The real time PCR was performed in a ABI
PRISM 7500 FAST (Applied Biosystems, Foster City,
CA, USA) using the following program: a start cycle of
2 min at 50°C, one cycle of 10 min at 95°C, and 40 cycles
of 15 s at 95°C and 1 min at 60°C. The fluorescence sig-
nals were analyzed using the program Sequence Detec-
tion Software V 1.2.3 (Applied Biosystems, Foster City,
USA) that generates clusters of signal amplification
which allow the identification of each genotype. Samples
with each genotype were analyzed together as an in-
ternal control.
The IL6 -174G > C (rs1800795) SNP was detected by
PCR-RFLP. The PCR primers were designed based on
the IL6 sequence [NM_000600] (GenBank, NIH/NCBI)
using the Primer Premier® v.5.0 software (PremierBiosoft
International, USA), as follows: forward, 5′-TGACTT-
CAGCTTTACTCTTTGT-3′; and reverse, 5′-CTGAT
TGGAAACCTTATTAA-3′. The genotypes were identi-
fied by an end point PCR assay, using 50 ng DNA,
200 nmol/L primers (IDT, Coralville, IA, USA),
200 μmol/L dNTPs (GE Healthcare, Amersham Biosci-
ences do Brasil, São Paulo, Brazil), 1 U DNA polymerase
(BioTools, Madrid, Spain), PCR buffer [75 mM Tris–
HCl (pH 9.0), 50 mM KCl, 20 mM (NH4) 2SO4,
2 mmol/L MgCl2] in 50 μL. PCR assays were carried out
in a Mastercycler® (Eppendorf AG, Hamburg, Germany)
using the following program: a cycle of 95°C for 1 min,
30 cycles of 95°C for 1 min, 59°C for 1 min and 72°C
for 1 min; and a cycle of 72°C for 10 min. The
226pb-amplicon was digested with the endonuclease Nla
III according to the manufacturer (New England Biolabs
Inc., Ipswich, MA, USA). Restriction fragments were
identified by 2% agarose gel eletrophoresis.
DNA genotyping results were interpreted by two inde-
pendent analysts and 20% of DNA samples were ran-
domly re-analyzed.
Statistical analysis
The results were analyzed using the SigmaStat v. 2.03
(Systat software Inc., San Jose, CA, USA) and Minitab
v.15 statistical software (Minitab Inc. State College, PA,
USA), assuming significance level of p < 0.05. Chi-square
test was used to compare categorical variables and the
agreement of genotypes frequencies with Hardy-
Weinberg equilibrium (HWE) expectations. Continuous
variables were compared by t-test or Mann–Whitney
Rank sum test, as well as ANOVA and Kruskal Wallis
with all pairwise multiple comparison using Holm-Sidak
and Dunn methods, respectively. Multiple linear regression
analysis was used to establish correlations between body
mass index and independent variables, considering the co-
variates: age, gender, ethnics, hypertension, tobacco smok-
ing, alcohol consumption, physical exercise practice,
T2DM and CAD. Nominal logistic regression analysis was
performed to evaluate the influence of clinical, biochemical
and genetic parameters on the risk for overweight and
obesity, using the normoweith as reference group.
Results
Table 1 shows clinical, anthropometrics and laboratory
data of the individuals enrolled in this study. Female was
the predominant gender in this sample, with higher pro-
portion in normoweight than in overweight and obese
groups (p = 0.035). On the other hand, menopause,
hypertension, T2DM was less frequent in normoweight
individuals (p < 0.05), while obese group was less prone
to practice of physical activity (p = 0.003). Mean age, eth-
nics, family history of CAD, tobacco smoking and alco-
hol consumption had similar values among the studied
groups (p > 0.05). As expected, measurements of BMI,
waist circumference, WHR, body fat content and BMR
were higher in the obese group and lower in normo-
weight group (p < 0.001). The leptinemia was higher and
sLEPR levels were lower in obese compared with those
from normoweight individuals (p < 0.05), while no differ-
ences were found in adiponectin plasma concentration
among the groups (p > 0.05).
Obese subjects had higher levels of glucose, HbA1c,
HOMA-β and HOMA-IR than normoweight group
(p < 0.05). Obeses also had a more atherogenic profile
with higher levels of LDL and VLDL cholesterol, trygli-
cerides and apoB and lower HDL cholesterol and apoAI
compared with the normoweight group (p < 0.05). The
values of fibrinogen, PAI-1, IL-6, IL-1β, TNFα and
hsCRP were also higher in obese than in normoweight
subjects (p < 0.05) (Table 1).
Results from multiple linear regression analysis con-
firmed that waist circumference, WHR and body fat
were positively correlated with BMI values (p < 0.001)
(Table 2). In addition, an increment of one unit in the
plasma concentration of leptin, IL-1β, hsCRP, TNFα,
PAI-1 and fibrinogen were related respectively with an
increase of 0.12, 0.11, 0.31, 0.35, 0.12, 0.02 Kg/m2 of
BMI in the study group (p < 0.05).
Univariate logistic regression analysis was carried out
to evaluate the influence of clinical, biochemical and
genetic variables as risk factors for overweight and obes-
ity. As shown in Table 3, waist circumference, body fat
and dyslipidemia increased the risk for overweight and
obesity in this sample (p < 0.05). In addition, hyperten-
sion and T2DM increase more than four times the risk
for obesity (p < 0.001), while female gender and physical
activity reduce this risk (p < 0.05). Increased plasma
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Table 1 Clinical, anthropometrics, laboratory and polymorphism data of the studied group
Variable Normoweight (51) Overweight (53) Obese (145) P-value
Age, years 46.6. ± 8.3 47.9 ± 6.9 48.7 ± 9.2 0.323
Ethnics [White], % 78.4 (40) 69.8 (37) 71.0(103) 0.539
Woman, % 92.2 (47) 79.2 (42) 75.2 (109) 0.035
Menopause,% 10.6 (5) 26.2 (11) 33.9 (37) 0.011
Hypertension, % 13.7 (7) 28.3 (15) 45.5 (66) <0.001
Type 2 diabetes, % 33.3 (17) 41.5 (22) 55.7 (99) <0.001
Family history of CAD 11.7 (6) 20.8 (11) 17.9 (26) 0.455
Tobacco smoking,% 17.6 (9) 23.2 (10) 13.1 (19) 0.527
Alcohol consumption, % 2.0 (1) 3.8 (2) 3.4 (5) 0.845
Physical exercise practice,% 50.9 (26) 50.9 (27) 29.6 (43) 0.003
Body mass index, kg/m2 22.6 ± 1.7a 27.4 ± 1.4b 35.1 ± 4.2c <0.001
Waist circumference, cm 73.9 ± 8.7a 86.8 ± 9.4b 104.1 ± 11.0c <0.001
Waist- hip ratio 0.78 ± 0.07a 0.84 ± 0.08b 0.90 ± 0.10 c <0.001
Body fat, % 30.9 ± 4.7a 33.9 ± 6.4b 38.5 ± 5.0c <0.001
BMR, kcal 1272 ± 240a 1501 ± 295b 1742 ± 280c <0.001
Leptin, ng/mL 13.6 ± 8.1a 15.7 ± 12.0a,b 22.9 ± 19.2b 0.012
sLEPR, ng/mL 23.8 ± 12.4a 19.1 ± 13.5a,b 20.0 ± 24.0b 0.011
Adiponectin, μg/mL 24.6 ± 23.2 17.7 ± 23.0 27.2 ± 26.4 0.070
Glucose, mg/dL 92 ± 9a 102 ± 26a,b 106 ± 29b <0.001
HbA1c, % 5.5 ± 0.4a 6.0 ± 1.3a,b 6.0 ± 1.4b 0.005
Insulin, mU/L 6.6 ± 4.3a 9.7 ± 6.1b 21.3 ± 12.2b <0.001
HOMA-β 23.0 ± 18.2a 33.3 ± 24.5b 68.7 ± 37.2b <0.001
HOMA-IR 1.5 ± 1.0a 2.4 ± 1.5b 5.9 ± 4.8b <0.001
Total cholesterol, mg/dL 194 ± 36 203 ± 37 209 ± 40 0.077
HDL ccholesterol, mg/dL 65 ± 19a 55 ± 17b 51 ± 12b <0.001
LDL cholesterol, mg/dL 113 ± 32a 125 ± 32a,b 128 ± 32b 0.016
VLDL cholesterol, mg/dL 16 ± 8a 23 ± 10b 30 ± 18c <0.001
Triglycerids, mg/dL 79 ± 38a 114 ± 53b 150 ± 88c <0.001
Apolipoprotein AI, mg/dL 160 ± 40a 152 ± 36a,b 146 ± 31b 0.009
Apolipoprotein B, mg/dL 89 ± 28a 109 ± 38b 101 ± 28b 0.004
Fibrinogen, mg/dL 341 (304–374)a 350 (319–409)a,b 374 (328–446)b <0.001
PAI-1, ng/mL 62.5 (44.7-76.1)a 63.6 (51.0-95.4)a 96.1(60.0-150.6)b <0.001
IL-6, pg/mL 0.08 (0.07-0.09)a 0.09 (0.08-0.55)a,b 0.56 (0.28-1.6)c <0.001
IL-1β, pg/dL 5.0 (4.0-5.6)a 5.9 (4.0-6.1)a,b 18.0 (15.0-51.5)c <0.001
hsCRP, mg/L 0.14 (0.05-0.58)a 0.49 (0.08-1.17)a,b 1.72 (0.26-5.69)c <0.001
TNFα, pg/mL 0.56 (0.09-1.25)a 0.71 (0.32-2.85)a,b 3.17 (1.45-6.05)c <0.001
Minor Allele Frequency, %
ADIPOQ 45 T > G (rs2241766) 19.6 22.6 21.7 0.858
IL6 -174G > C (rs1800795) 26.4 37.7 31.0 0.209
Number of individuals is in parenthesis. Results are shown as mean ± SD or median (interquartile range) and compared by Anova (Multiple comparisons by
Holm-Sidak method) or Kruskal Wallis (Dunn’s Method). Different letters indicate differences between mean values. Categorical variables were compared by
chi-square. BMR: basal metabolic rate; CAD: coronary artery disease; HDL: high-density lipoprotein; hsCRP: high sensitive C reactive protein; LDL: low-density
lipoprotein; PAI-1: plasminogen activator inhibitor-1; IL-6: interleukin 6; IL-1β: interleukin 1beta; sLEPR: soluble leptin receptor; TNFα: tumor necrosis factor alpha;
VLDL: very low-density lipoprotein.
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levels of both fibrinogen and IL-1β were associated with
high risk for overweight and obesity (p < 0.05) (Table 3).
Moreover, increased leptin, hsCRP and TNFα concentra-
tions were also risk factors for obesity (p < 0.05).
ADIPOQ 45 T > G and IL6 -174G > C SNPs had geno-
type distributions as expected from HWE in this sample
(Data not shown). Minor allele frequencies of these vari-
ants were similar between obese, overweight and normo-
weight groups (p > 0.05) (Table 1). These variants did
not show significant association with neither BMI
(Table 2) nor risk for overwheight and obesity (table 3) in
this sample. Interestingly, individuals carrying ADIPOQ
45G allele (TG +GG genotype) had higher IL-6, IL-1β and
TNFα plasma levels than TT genotype carriers (p < 0.05)
(Figure 1, Table 4). While IL6 -174GG genotype was asso-
ciated with higher levels of IL-1β (p = 0.033) (Figure 1,
Table 5).
Discussion
Results from this study demonstrate an association of
obesity with hypertension, T2DM, insulin resistance and
an atherogenic lipid profile, confirming that overweight
and obese individuals are more susceptible to metabolic
dysfunction and atherosclerosis, which are known risk
factors for CVD [21].
The hyperleptinemia and reduced sLEPR found in
overweight and obese patients indicate a status of leptin
resistance, which is probably caused by dysregulation of
the negative feedback, as a classic mechanism of hor-
mone resistance [22]. It is well known that hyperleptine-
mia triggers a chronic overstimulation of the leptin
receptor and activation of negative feedback pathways
that block further leptin signaling, leading to leptin re-
sistance (22). The hyperleptinemia has been attributed
to a deficiency in leptin transport through the blood–
brain barrier, as well as, to the presence of variants in
LEPR, which alters funcionatily or even expression of
the receptor reducing its circulating levels, as found in
obese subjects.
It has been suggested that resistance to leptin produce
metabolic and inflammatory alterations in several tissues
and organs, including the liver, spleen and heart, there-
fore leptin resistance contributes to the risk for obesity-
related comorbidities [23].
In this work, obesity was associated with hypergly-
cemia, insulin resistance and dyslipidemia. Obese pa-
tients have reduced supply of glucose in adipocytes that
leads to a decreased intracellular lipolysis and increased
release of non-esterified fatty acids, which results in in-
sulin resistance, dysglycemia and dyslipidemia [24].
These metabolic alterations increase the risk for CVD in
obese subjects.
We could not find a direct relationship of the ADI-
POQ 45 T > G polymorphism with obesity or variability
in body fat mass, waist circumference and BMI values.
Similarly, this variant was not associated with BMI in
other groups such as Mexican-Mestizos [25], Tunisian
volunteers [26], Saudi Arabians [27] and Chinese [28].
This lack of association was also found in groups of
women [29] or men [10,11] suggesting that is independ-
ent on gender.
The ADIPOQ 45 T > G variant has been shown to be
associated with variability in adiponectin levels in several
studies including in overweight Finish subjects with im-
paired glucose tolerance [12], diabetic and non-diabetic
Brazilian patients with high cardiovascular risk [15],
Arab patients with acute coronary syndrome [30]. How-
ever, this relationship was not found in our study and in
other population samples [25-29], including patients
with coronary artery disease [31,32].
We did not find an association between IL6 -174G > C
SNP and obesity or variability in BMI. A large study with
two independent cohorts has indicated that IL6 variants
are significantly associated with adiposity, but the contri-
bution of the SNP -174G > C seems to be less likely [33].
Lack of relationship of this variant and obesity was also
found in children [34], adolescents [35] and diabetic
adults [36] suggesting that it is not a major contributor
to obesity risk.
Table 2 Anthropometric, biochemical and genetic
variables as predictors for body mass index values:
multiple linear regression analysis
Independent variables B SE P-value
Anthopometrics
Waist circumference, cm 0.361 0.017 <0.001
Body fat, % 0.840 0.055 <0.001
Waist-hip ratio 21.317 4.397 <0.001
Biochemical parameters
Fibrinogen, mg/dL 0.021 0.004 <0.001
PAI-1, pg/mL 0.121 0.038 0.002
hsCRP, mg/L 0.31 0.07 <0.001
IL-6, pg/mL −0.006 0.118 0.962
IL-1β, pg/dL 0.110 0.018 <0.001
TNFα, pg/mL 0.348 0.130 0.008
Adiponectin, μg/mL 0.0023 0.0170 0.890
Leptin, ng/mL 0.120 0.024 <0.001
sLEPR, ng/mL 0.0007 0.0232 0.975
Polymorphisms
ADIPOQ 45 T > G (ref TT) 0.259 0.773 0.738
IL6 -174G > C (ref GG) 0.099 0.740 0.893
Regression coefficients (B) and standard errors (SE) are expressed in kg/m2.
Age, gender, ethnics, hypertension, tobacco smoking, alcohol consumption,
physical exercise practice, T2DM and CAD were used as covariates. Polymorphisms
were introduced as dummy variables for absence or presence of the rare allele.
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Table 3 Influence of clinical, biochemical and genetic variables on the risk for overweight and obesity: Univariate
logistic regression analysis
Independent variables Risk for overweight Risk for Obesity
OR 95% CI P-value OR 95% CI P-value
Clinical and anthropometric variables
Age, years 1.02 0.97 – 1.06 0.453 1.03 0.99 – 1.07 0.145
Gender [ref: male] 0.37 0.11 – 1.25 0.110 0.25 0.08 – 0.73 0.011
Ethnics [ref: white] 0.64 0.26 – 1.55 0.318 0.67 0.31 – 1.43 0.297
Menopause 1.13 0.50 – 2.52 0.774 0.54 0.27 – 1.08 0.081
Hypertension 2.48 0.92 – 6.72 0.074 5.32 2.25 – 12.60 <0.001
T2DM 1.42 0.64 – 3.15 0.390 4.40 2.23 – 8.69 <0.001
Dyslipidemia 3.30 1.48 – 7.38 0.004 5.02 2.53 – 9.97 <0.001
Family history of CAD
Tobacco smoking 1.09 0.40 – 2.94 0.872 0.71 0.30 – 1.69 0.437
Alcohol consumption 1.96 0.17 – 22.32 0.587 1.80 0.21 -15.77 0.596
Physical exercise practice 0.93 0.43 – 2.00 0.845 0.41 0.21 – 0.79 0.008
Waist circumference, cm 1.21 1.12 – 1.30 <0.001 1.42 1.30 – 1.55 <0.001
Body fat, % 1.13 1.04 – 1.23 0.004 1.34 1.23 – 1.46 <0.001
Biochemical parameters
Leptin, ng/mL 1.02 0.98 – 1.06 0.434 1.05 1.01 – 1.08 0.006
sLEPR, ng/mL 0.99 0.90 – 1.01 0.397 0.99 0.97 – 1.01 0.421
Adiponectin, μg/mL 0.99 0.97–- 1.01 0.155 1.00 0.99 – 1.02 0.555
Fibrinogen, mg/dL 1.01 1.00 – 1.01 0.037 1.01 1.00 – 1.01 <0.001
PAI-1, pg/mL 1.03 0.98 – 1.08 0.204 1.04 1.00 – 1.08 0.057
IL-6, pg/mL 1.23 0.91 – 1.67 0.183 1.24 0.92 – 1.66 0.154
IL-1β, pg/dL 1.08 1.01 – 1.16 0.029 1.14 1.06 – 1.22 <0.001
hsCRP, mg/L 1.24 0.87 – 1.76 0.232 1.75 1.28 – 2.3 <0.001
TNFα, pg/mL 1.18 0.96 – 1.45 0.123 1.35 1.13 – 1.62 0.001
Polymorphisms
ADIPOQ 45 T > G (ref TT) 1.03 0.46 - 2.32 0.946 1.06 0.54 - 2.09 0.858
IL6 -174G > C (ref GG) 1.50 0.68 - 3.30 0.317 0.95 0.50 - 1.81 0.884
Results obtained from a univariate nominal regression analysis using the normoweight subjects as reference group. OR, odds ratio; CI, confidence interval.
Polymorphisms were introduced as dummy variables for absence or presence of the rare allele.
Figure 1 Influence of ADIPOQ 45 T > G and IL6 -174G > C polymorphisms on plasma inflammatory biomarkers. Box plots represent plasma
concentration of IL-6, IL-1β and TNF-α according to ADIPOQ 45 T > G and IL6 -174G > C genotypes. Values of wild type genotypes (WT) were
compared with variant allele carriers for each polymorphism using the Mann–Whitney Rank sum test. p-values are indicated in the figure for each
comparison. NS: no significant.
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In this study, BMI was positively correlated with circu-
lating levels of pro-inflammatory such as fibrinogen,
PAI-1, hsCRP, IL-1β, and IL-6 and TNFα. Moreover, al-
tered levels in most of these pro-inflammatory markers
were associated with increased risk for obesity. These re-
sults confirm previous studies, which suggested that the
expansion of the adipose tissue favours the development
of a pro-inflammatory, diabetogenic and atherogenic
status [3,4].
We also found that variability in TNFα, IL-1β and IL-
6 circulating levels was associated with ADIPOQ 45 T >
G SNP, suggesting a role of this variant in regulation of
the pro-inflammatory status in obese subjects. Guzman-
Ornelas et al. have also found an association of ADIPOQ
45 T > G SNP with a pattern of fat distribution and cor-
relations with inflammation markers, but not directely
related to the genotypes [26].
IL6 -174G > C SNP did not influence the IL-6 circu-
lating levels as it has been shown in a study with Span-
ish adolescents that demonstrated an association
between fat mass and cardiovascular risk factor [37].
Conversely, in Italian Caucasian females, increased
plasma levels of IL-6 were found in obese individuals
carrying GG genotype suggesting that fat mass is a
major determinant of an increase in IL-6 production
and insulin resistance [38].
Table 4 Relationship of ADIPOQ 45 T > G with
anthropometric, metabolic and inflammatory variables
Variable Genotypes
TT (163) TG + GG (86) P-value
Body mass index, kg/m2 30.9 ± 6.2 31.1 ± 6.2b 0.818
Waist circumference, cm 94.4 ± 16.4 94.1 ± 15.3 0.881
Waist- hip ratio 0.86 ± 0.10 0.87 ± 0.10 0.249
Body fat, % 35.8 ± 6.0 36.3 ± 6.5 0.527
BMR, kcal 1611 ± 336 1530 ± 328 0.190
Leptin, ng/mL 20.5 ± 17.6 18.8 ± 15.8 0.666
sLEPR, ng/mL 21.0 ± 21.9 19.6 ± 18.6 0.614
Adiponectin, μg/mL 25.7 ± 25.4 21.5 ± 24.0 0.442
Glucose, mg/dL 101 ± 25 104 ± 27 0.464
HbA1c, % 5.9 ± 1.2 5.9 ± 1.3 0.476
Insulin, mU/L 15.3 ± 1.6 17.6 ± 12.7 0.181
HOMA-β 50.7 ± 38.6 56.0 ± 35.3 0.205
HOMA-IR 4.1 ± 4.0 5.0 ± 4.8 0.153
Total cholesterol, mg/dL 205 ± 36 204 ± 43 0.663
HDL ccholesterol, mg/dL 55 ± 15 53 ± 16 0.205
LDL cholesterol, mg/dL 125 ± 32 124 ± 34 0.816
VLDL cholesterol, mg/dL 25 ± 14 27 ± 19 0.475
Triglycerides, mg/dL 124 ± 70 135 ± 93 0.475
Apolipoprotein AI, mg/dL 151 ± 35 148 ± 33 0.557
Apolipoprotein B, mg/dL 100 ± 27 100 ± 38 0.469
Fibrinogen, mg/dL 361 (319–423) 353 (316–399) 0.327
PAI-1, pg/mL 74.5 (55.4-138.8) 81.9 (58.2-137.7) 0.713
IL-6, pg/mL 0.28 (0.08-0.64) 0.54 (0.28-1.4) 0.012
IL-1β, pg/dL 14 (4.0-23.0) 22 (4.6-55.7) 0.003
hsCRP, mg/L 0.54 (0.1-3.1) 0.56 (0.14-3.0) 0.980
TNFα, pg/mL 1.45 (0.34-4.81) 2.9 (1.06-5.84) 0.031
Number of individuals is in parenthesis. Results are shown as mean ± SD or
median (interquartile range) and compared by Mann–Whitney Rank sum test.
BMR: basal metabolic rate; CAD: coronary artery disease; HDL: high-density
lipoprotein; LDL: low-density lipoprotein; hsCRP: high sensitive C reactive protein;
IL-6: interleukin 6; IL-1β: interleukin 1beta; PAI-1: plasminogen activator inhibitor-1;
sLEPR: soluble leptin receptor; TNFα: tumor necrosis factor alpha; VLDL: very
low-density lipoprotein.
Table 5 Relationship of IL6 -174G > C with
anthropometric, metabolic and inflammatory variables
Variable Genotypes
GG (112) GC + CC (137) P-value
Body mass index, kg/m2 31.2 ± 6.1 30.7 ± 6.3 0.528
Waist circumference, cm 96.4 ± 16.1 92.6 ± 15.7 0.067
Waist- hip ratio 0.87 ± 0.10 0.85 ± 0.10 0.164
Body fat, % 35.5 ± 6.0 36.4 ± 6.2 0.246
BMR, kcal 1644 ± 373 1543 ± 298 0.057
Leptin, ng/mL 21.8 ± 18.6 18.6 ± 15.6 0.394
sLEPR, ng/mL 22.4 ± 23.3 19.2 ± 18.8 0.615
Adiponectin, μg/mL 24.0 ± 24.0 24.5 ± 25.9 0.755
Glucose, mg/dL 103 ± 31 102 ± 21 0.072
HbA1c, % 6.0 ± 1.4 5.9 ± 1.1 0.876
Insulin, mU/L 17.7 ± 13.6 14.3 ± 9.8 0.237
HOMA-β 57.0 ± 40.3 47.4 ± 34.4 0.148
HOMA-IR 4.9 ± 5.3 3.7 ± 2.7 0.379
Total cholesterol, mg/dL 205 ± 42 204 ± 36 0.755
HDL ccholesterol, mg/dL 56 ± 19 54 ± 12 0.823
LDL cholesterol, mg/dL 122 ± 34 127 ± 31 0.241
VLDL cholesterol, mg/dL 26 ± 19 25 ± 13 0.759
Triglycerides, mg/dL 132 ± 94 124 ± 64 0.759
Apolipoprotein AI, mg/dL 152 ± 35 148 ± 34 0.753
Apolipoprotein B, mg/dL 101 ± 27 100 ± 34 0.462
Fibrinogen, mg/dL 355 (317–407) 365 (319–420) 0.325
PAI-1, pg/mL 82.7 (57.5-133.5) 75.2 (56.3-145.9) 0.991
IL-6, pg/mL 0.48 (0.08-0.64) 0.28 (0.08-0.96) 0.288
IL-1β, pg/dL 15.0 (4.0-45.0) 13.5 (4.0-32.0) 0.033
hsCRP, mg/L 0.57 (0.13-3.2) 0.52 (0.10-2.94) 0.808
TNFα, pg/mL 2.62 (0.41-4.92) 2.29 (0.49-5.18) 0.666
Number of individuals is in parenthesis. Results are shown as mean ± SD or
median (interquartile range) and compared by Mann–Whitney Rank sum test.
BMR: basal metabolic rate; CAD: coronary artery disease; HDL: high-density
lipoprotein; LDL: low-density lipoprotein; hsCRP: high sensitive C reactive protein;
IL-6: interleukin 6; IL-1β: interleukin 1beta; PAI-1: plasminogen activator inhibitor-1;
sLEPR: soluble leptin receptor; TNFα: tumor necrosis factor alpha; VLDL: very
low-density lipoprotein.
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IL-1β levels were influenced by IL6 -174G > C SNP in
this sample, with high levels found in individuals carry-
ing GG genotype compared to C allele (GC + CC geno-
types) carriers. In a similar way, Mendoza-Carrera et al.
found an association between C allele and low hsCRP
levels in the overweight adolescents [35]. Moreover
Ramírez-López et al. reported a relationship between
GCG/GCG haplotype from IL6 -597G > A, −572G > C
and -174G > C SNPs and high hsCRP [39]. These results
are suggestive of a protective effect of the IL6 -174G > C
variant on inflammatory status of obese individuals.
Even though the results from this study are interesting
the lack of association between ADIPOQ variant and
obesity and adiponectin levels may be influenced by the
heterogeneity and size of our sample population and also
environmental factors.
Conclusion
The results from this study confirm that obesity is asso-
ciated with cardiometabolic alterations, leptin resistance
and a pro-inflammatory status. Our results are suggest-
ive that ADIPOQ and IL6 polymorphisms contribute to
cardiometabolic risk in obese individuals; however, more
studies using higher sample sizes are needed to confirm
the associations observed in this work.
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